What Attia and Huberman actually say about GLP-1 dosing

Peter Attia and Andrew Huberman are two of the credentialed clinicians with the largest audiences talking about peptides. If you have read anything about GLP-1 drugs in the last two years, you have probably encountered one of them second-hand.

Both have covered GLP-1 extensively. Here is the honest summary, with the parts people misquote.

Peter Attia

Attia has covered GLP-1 drugs on The Drive podcast across several episodes. His posture, roughly:

On efficacy: the drugs work. The weight-loss numbers in SURMOUNT-1 and STEP-1 are real, not trial artifacts. Most of his skepticism about weight-loss drugs in the 2010s was reset by the 2022-2023 data.

On patient selection: he is comfortable prescribing GLP-1 agonists to the right patient. The right patient is typically someone with BMI above 30, or BMI above 27 with metabolic comorbidity, who has tried and failed structured lifestyle intervention.

On dosing and duration: he has repeatedly noted that the drugs are chronic-use drugs for most patients. Stopping them generally leads to weight regain. He frames this as similar to any other chronic metabolic management , not a failure of the drug, but a feature of how metabolism works.

On side effects: Attia has been willing to discuss the thyroid C-cell warning in detail. His read: the rat-data relevance to humans is uncertain but not zero; patients with personal or family history of medullary thyroid cancer should not take these drugs; everyone else is in an acceptable risk envelope given the metabolic benefit.

The nuance he adds that most writeups skip: muscle mass loss during weight loss on GLP-1s is real and requires deliberate protein intake and resistance training to mitigate. He has been firm about this. If you lose 20% body weight and 30% of that is muscle, you are thinner but functionally worse off.

Andrew Huberman

Huberman hosted Dr. Sean O'Mara on GLP-1 dosing and risk in a long-form conversation. Huberman's own commentary is more cautious than Attia's in some ways, more permissive in others.

On efficacy: acknowledged strongly. The weight-loss data is not controversial.

On mechanism: Huberman emphasized the neural side , GLP-1 activity in the brain affects reward signaling, food cue responsiveness, and sometimes non-food reward behaviors (alcohol, compulsive shopping). This is an active research area and one of the more interesting parts of the drug profile.

On patient selection: Huberman's posture is closer to "these are serious drugs for serious problems." He is less enthusiastic than Attia about using GLP-1 drugs for cosmetic or mild-indication weight loss.

On the stopping question: he discussed the rebound-weight-gain issue more critically, framing it as a reason to be thoughtful about starting.

On sleep and GI: Huberman has flagged the GI side effects more prominently, especially for users with pre-existing gut issues.

What they agree on

• The drugs work.
• They are chronic-use drugs for most patients.
• Side effects are manageable for most, dealbreakers for a minority.
• Muscle preservation during weight loss is important and often neglected.
• The thyroid C-cell warning is a real contraindication for the relevant history; not a contraindication for everyone else.
• Not a replacement for lifestyle intervention, but a real tool when lifestyle alone has not worked.

What they disagree on, or emphasize differently

• Attia frames GLP-1 drugs as one more tool in a metabolic-health toolkit, similar in category to statins or metformin. Use when indicated.
• Huberman frames them as serious interventions that deserve more skepticism than the popular coverage suggests. Use when there is a real problem to solve.

Both views are defensible. The right frame for you depends on how close you are to the edge cases.

The sources

Panya's source library anchors on Tier 2 authorities like Attia and Huberman for interpretive framing, and on Tier 1 peer-reviewed trials (SURMOUNT, STEP, SURPASS) for the underlying data. We cite two authorities per user-facing claim. Overciting reads like defense, underciting reads like hype.

If you want a routed match

Take our quiz. We email you a match within 24 to 48 hours. One email. No list.